Silexion Therapeutics Gains Israeli Approval for Pivotal Phase 2/3 Pancreatic Cancer Trial
SLXN is trading near its 52-week low of $1.21 (9.9% above the low).
Summary
Silexion Therapeutics has received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer. This marks a significant regulatory and operational milestone, advancing their lead candidate into pivotal human clinical evaluation following positive preclinical results and toxicology studies. This positive development is particularly critical given the company's recent financial challenges, including a "going concern" warning, limited cash, and shareholders rejecting a proposal to increase authorized share capital. The approval provides a much-needed validation of the company's pipeline and could be instrumental in attracting future financing or partnerships. Investors will now watch closely for the company's ability to secure the necessary funding to commence and progress this trial, as well as planned regulatory submissions in Germany and the EU.
At the time of this announcement, SLXN was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $1.21 to $22.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.